Panelists discuss the primary access challenges in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) treatment, including financial barriers and health care system limitations, and how ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

Zanubrutinib plus venetoclax elicited durable responses in patients with treatment-naïve CLL or SLL and high-risk genetic features.

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

The safety profile was consistent with previous studies, with no new safety signals. These results reinforce BeOne Medicines ...

Although there has been steady uptake of targeted therapies across LOTs, unmet need persists for patients with CLL/SLL who receive later LOTs. The time to the next treatment decreased with each LOT, ...

People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of ...

After running the Boston Marathon at 67, I faced new limits from aging and chronic lymphocytic leukemia — but I’ve found ways ...

A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual ...

The latest news from ASCO 2025 focusing on CLL including abstracts, features, and helpful conference information.

Farmers use herbicides like Roundup to kill weeds, preventing them from destroying crops. But in recent years, Bayer, which ...

HealthDay News — For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), statin use is associated with improved survival, regardless of treatment employed, according ...